Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division January 23, 2020
Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock November 29, 2019
